Basket | Login | Register


EU Action on Dementia

Since Alzheimer Europe presented its political priorities embedded in the "Paris Declaration" in 2006, a series of European developments have put dementia on the European agenda.

Thanks to the combined efforts of Alzheimer Europe, its members and the political support of the Members of the European Parliament as well of national policy makers, EU action on dementia has become a reality.




2015 European Parliament Written Declaration


EPSCO Council adopts Luxembourg EU Presidency conclusions, with an emphasis on supporting people with dementia


Launch of "IMI 2" by the Innovative Medicines Initiative

Neurodegenerative diseases and age-associated diseases are among the priorities of the Strategic Research Agenda. IMI (2) aims at reaching a 30% better success rate in clinical trials of priority medicines identified by the WHO; clinical proof of concept in immunological, respiratory, neurological and neurodegenerative diseases in just five years; new and approved diagnostic markers for four of these diseases and at least two new medicines which could either be new antibiotics or new therapies for Alzheimer’s disease.

6 May 2014

Council Regulation (EU) No 557/2014 establishing the Innovative Medicines Initiative 2 Joint Undertaking

March 2014

European Commission 3rd Health Programme (Regulation (EU) No 282/2014 of the European Parliament and of the Council of 11 March 2014 on the establishment of a third Programme for the Union's action in the field of health (2014-2020) and repealing Decision No 1350/2007/EC).

One of the thematic priorities includes ‘support cooperation and networking in the Union in relation to preventing and improving the response to chronic diseases including cancer, age-related diseases and neurodegenerative diseases, by sharing knowledge, good practices and developing joint activities on prevention, early detection and management (including health literacy and self management)’.


Launch of Horizon 2020, the European Commission Research and Innovation Programme. Horizon 2020 will cover societal challenges such as health, demographic change and well-being. Research & Innovation supported by this programme will improve our understanding of the causes and mechanisms underlying health, healthy ageing and disease; improve our ability to monitor health and to prevent, detect, treat and manage disease; support older persons to remain active and healthy; and test and demonstrate new models and tools for health and care delivery.

28 March 2013

Presentation of the ALCOVE project results, recommendations and anti-psychotic toolbox

7 February 2012

JPND: launch of the European Research Strategy

7 November 2011

Presentation of the Strategic Implementation Plan of the European Innovation Partnership on Active and Healthy Ageing (EIP AHA)


Launch of ALCOVE, the EU Joint Action on Dementia (2011-2013)

19 January 2011

European Parliament Resolution on a European Initiative on Alzheimer’s disease and other dementias

9 December 2010

European Parliament Report on a European initiative on Alzheimer’s disease and other dementias

25 November 2010

Belgium EU Presidency conference on dementia: "Improving the quality of life of people with dementia: A challenge for European society"

10 April 2010

Launch of the JPND

March 2010

Spanish EU Presidency holds conference on "Mental Health and Well-Being in Older People – Making it Happen"

9 December 2009

European Parliament Resolution on  the Joint Programming of research to combat Neurodegenerative Diseases, particularly Alzheimer’s disease

1 December 2009

Council of Ministers issues conclusions on "Dignified ageing"

15-16 September 2009

Swedish EU presidency holds conference on "Healthy and Dignified Ageing"

22 July 2009

European Commission adopts Proposal for a Council Recommendation on measures to combat neurodegenerative diseases, in particular Alzheimer's, through joint programming of research activities and Communication on a European initiative on Alzheimer’s disease and other dementias

6 February 2009

European Parliament adopts Written Declaration 80/2008 calling on Commission to adopt a European Action plan on dementia

17 December 2008

Council of Ministers calls for greater European collaboration on Alzheimer's disease and asks European Commission to develop European Alzheimer's initiative

30-31 October 2008

French Presidency of the European Union organises two-day conference on the fight against Alzheimer's disease

2 July 2008

French President Sarkozy & Commission President Barroso announce a European initiative on Alzheimer’s disease

15 February  2008

Innovative Medicines Initiative (IMI)

IMI Research Agenda includes  the ‘Improved Predictivity of Efficacy Evaluation for brain disorders’, and  more specifically, in the field of dementia : the identification and validation of pre-symptomatic and surrogate markers for disease progression, the development of model systems that translate to human pathology and are predictive of clinical efficacy, better understanding of disease mechanisms  for improved target selection




Council Regulation (EC) No 73/2008 setting up the Joint Undertaking for the implementation of the Joint Technology Initiative on

Innovative Medicines


European Commission's Research Programe - FP7(Framework Programme 7)  emphasized collaborative research with a specific sub activity on "Research on the brain and related diseases, human development and ageing". Particular emphasis was placed on translational research, for bringing knowledge from bench to bedside and for development of new drug targets.

23 October


European Commission  White PaperCOM(2007) 630 final “Together for Health: A Strategic Approach for the EU 2008-

2013” developing the EU Health Strategy also identifies the better understanding of neurodegenerative diseases such as Alzheimer's as important needs to address.


Alzheimer Europe Paris Declaration   


Last Updated: Thursday 07 January 2016